Sling Therapeutics

We had an article on cracking the genetic code of psoriasis.

Sling Therapeutics raised $123 million for a Phase 3 thyroid eye disease study.

And a South Korean study found a way to redirect cell state with a single stimulus.

Insilico launched its AI-driven longevity vaccines research.

And finally, a financing story out of the eye disease world.

A biotech called Sling Therapeutics raised $123 million in a Series C round to push forward a Phase III trial of an oral pill for thyroid eye disease, a condition that causes the eyes to bulge and swell.

Right now, the approved treatments for this condition are all antibodies that have to be injected or infused.

Sling's drug, called linsitinib, is a pill taken twice a day, and in an earlier trial, it showed a good response rate without some of the side effects, like hearing loss, that have been an issue with the injectable options.

This reflects a broader industry trend emphasizing improved drug delivery systems to boost treatment efficacy and patient outcomes.

On the clinical advancement front, Sling Therapeutics has raised one hundred twenty-three million dollars in a Series C funding round aimed at propelling its oral therapy for thyroid eye disease forward.

Unlike traditional intravenous treatments, this oral therapy offers a more convenient option for patients, potentially improving adherence and quality of life.

Meanwhile, Circle Pharma's ninety-two point five million dollar Series E funding will support the development of its cyclin D1 inhibitor for breast cancer, showcasing innovation in oncology through the use of macro cycles that could provide more effective treatments with fewer side effects.

In today's Pharmaceutical Executive Daily, Novo partners with Anthropic to tackle drug discovery bottlenecks with AI.

A biotech financing roundup covers Sling Therapeutics' one hundred and twenty-three million dollar Series C for its thyroid eye disease candidate, and Circle Pharma's ninety-two point five million dollar Series E for its oral cancer therapy.

And Phil Ford of IQVIA argues that pharma's medical content strategy needs to shift from a pipeline to a loop.

Novo partners with Anthropic to co-develop AI tools aimed at drug discovery bottlenecks, deploying Claude Science across select R&D workflows to speed biological reasoning and the path from research to new medicines.

The deal marks Novo's third major AI partnership of twenty twenty-six, following deals with OpenAI in April and Amazon Web Services in August.

Two clinical-stage biopharma financings closed this week as investors back next-generation autoimmune and oncology candidates.

Sling Therapeutics raises one hundred and twenty-three million dollars in a Series C led by Forbion, with participation from TPG Life Sciences Innovations and new investor Sectoral Asset Management to advance linsitinib, an oral IGF-1R inhibitor and the only one in late-stage development through the Phase Three ORBIT trial in thyroid eye disease.

Separately, Circle Pharma raises ninety-two point five million dollars in a Series E led by the Column Group with Eli Lilly and Company among the investors to advance CID-one sixty-five, a first-in-class oral macrocyclic cyclin D1RXL inhibitor moving toward early clinical development in ER-positive breast cancer.